Press Releases and Media Coverage
November 3, 2025
Drug Target Review: CD24 Emerges as the Next Macrophage Checkpoint
November 3, 2025
Drug Target Review: CD24 Emerges as the Next Macrophage Checkpoint
June 9, 2025
OncoLife: Targeting the “Don’t Eat Me Signal,” The Future of Macrophage Checkpoint Inhibitors in Oncology
June 9, 2025
OncoLife: Targeting the “Don’t Eat Me Signal,” The Future of Macrophage Checkpoint Inhibitors in Oncology
June 3, 2025
Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer
June 3, 2025
Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer
April 14, 2025
Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Solid Tumors
April 14, 2025
Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Solid Tumors
February 18, 2025
Pheast Appoints Dr. Raphaël Rousseau as Chief Medical Officer
February 18, 2025
Pheast Appoints Dr. Raphaël Rousseau as Chief Medical Officer
December 2, 2024
The Bio Report Podcast: Getting Tumors to Say “Eat Me”
December 2, 2024
The Bio Report Podcast: Getting Tumors to Say “Eat Me”
November 8, 2024
The Cancer Letter: Preclinical Data Show Anti-CD24 Macrophage Checkpoint Inhibitor Promotes Phagocytosis and Shrinks Tumors
November 8, 2024
The Cancer Letter: Preclinical Data Show Anti-CD24 Macrophage Checkpoint Inhibitor Promotes Phagocytosis and Shrinks Tumors
November 7, 2024
Pheast Presents New Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor, at SITC 2024
November 7, 2024
Pheast Presents New Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor, at SITC 2024
November 6, 2024
GEN: Parallel Platform Approach Slashes Process Development Time
November 6, 2024
GEN: Parallel Platform Approach Slashes Process Development Time
September 3, 2024
Drug Discovery Online: Does Targeting Macrophages Hold The Key For Treating Cancer?
September 3, 2024
Drug Discovery Online: Does Targeting Macrophages Hold The Key For Treating Cancer?
July 31, 2024
Cancer Research: Attacking Cancer Through Activating “Big Eaters” of the Immune System
July 31, 2024
Cancer Research: Attacking Cancer Through Activating “Big Eaters” of the Immune System
June 26, 2024
PharmaShots: Macrophage Checkpoint Therapy with Roy Maute from Pheast Therapeutics
June 26, 2024
PharmaShots: Macrophage Checkpoint Therapy with Roy Maute from Pheast Therapeutics
May 13, 2024
Pheast Unveils First Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor
May 13, 2024
Pheast Unveils First Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor
January 5, 2024
Drug Target Review: The Potential of CD24 in Cancer Immunotherapy
January 5, 2024
Drug Target Review: The Potential of CD24 in Cancer Immunotherapy
November 15, 2023
Pheast Featured as One of Nature Biotechnology’s Top Academic Spinouts for 2023
November 15, 2023
Pheast Featured as One of Nature Biotechnology’s Top Academic Spinouts for 2023
April 26, 2022
Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer
April 26, 2022
Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer
